Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Ahsan Farooqi

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Radiology

50%

Pharmacotherapy

60%

Oncology

90%

Radiation Therapy

50%

Sarcoma Research

40%

Solid Tumor

30%

Cancer Therapy

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT‐STS): Updated local control, late toxicities, and patient‐reported outcomes

Article Link

Year:

2024

Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma

Article Link

Year:

2024

Outcomes for patients with head and neck sarcoma treated curatively with radiation therapy and surgery.

Article Link

Year:

2024

High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience

Article Link

Year:

2024

Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes

Article Link

Year:

2023

Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease.

Article Link

Year:

2023

Radiation Therapy for Retroperitoneal Sarcomas: A Strass-Ful Situation

Article Link

Year:

2023

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival

Article Link

Year:

2023

Safety and Efficacy of Dose-Escalated Radiation Therapy With a Simultaneous Integrated Boost for the Treatment of Spinal Metastases

Article Link

Year:

2023

SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.

Article Link

Year:

2023

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.

Article Link

Year:

2022

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.

Article Link

Year:

2022

Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.

Article Link

Year:

2022

Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma.

Article Link

Year:

2022

Cardiac Angiosarcomas: Risk of Brain Metastasis and Hemorrhage Warrants Frequent Surveillance Imaging and Early Intervention

Article Link

Year:

2022

Collaborators12

Lewis Nasr

The University of Texas MD Anderson Cancer Center

UNITED STATES

B. Ashleigh Guadagnolo

Professor

MD Anderson Cancer Center

UNITED STATES

Russell Witt

Assistant Professor

University of Virginia

UNITED STATES

Andrew Bishop

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Nandita Guha-Thakurta

The University of Texas MD Anderson Cancer Center

UNITED STATES

Elise Nassif

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Anthony P. Conley

The University of Texas MD Anderson Cancer Center

UNITED STATES

Roi Weiser

Assistant Professor

MD Anderson Cancer Center

UNITED STATES

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Ethan Ludmir

UNITED STATES

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES

Debra Nana Yeboa

The University of Texas MD Anderson Cancer Center

UNITED STATES

How do I reach out?

Meet Kite AI